{"id":"NCT00506415","sponsor":"Novartis Pharmaceuticals","briefTitle":"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline","officialTitle":"A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon速 10 and 15 cm^2 Patch in Patients With Mild to Moderate Alzheimer's Disease (AD) Showing Functional and Cognitive Decline","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2011-05","completion":"2011-05","firstPosted":"2007-07-25","resultsPosted":"2012-09-19","lastUpdate":"2012-09-19"},"enrollment":1584,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer Disease"],"interventions":[{"type":"DRUG","name":"Rivastigmine 5 cm^2","otherNames":["Exelon速"]},{"type":"DRUG","name":"Rivastigmine 10 cm^2","otherNames":["Exelon速"]},{"type":"DRUG","name":"Rivastigmine 15 cm^2","otherNames":["Exelon速"]},{"type":"DRUG","name":"Placebo to 15 cm^2 patch","otherNames":[]},{"type":"DRUG","name":"Placebo to 10 cm^2 patch","otherNames":[]}],"arms":[{"label":"Open label: Rivastigmine (5 cm^2 / 10 cm^2)","type":"EXPERIMENTAL"},{"label":"Double blind: Rivastigmine (10 cm^2)","type":"EXPERIMENTAL"},{"label":"Double blind: Rivastigmine (15 cm^2)","type":"EXPERIMENTAL"},{"label":"Extended open label Rivastigmine (10 cm^2)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of rivastigmine patch 10 cm\\^2.","primaryOutcome":{"measure":"Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Subscale at Week 48 of Double Blind Period","timeFrame":"Baseline and week 48 of double blind period","effectByArm":[{"arm":"Double Blind: Rivastigmine (10 cm^2)","deltaMin":4.9,"sd":7.49},{"arm":"Double Blind: Rivastigmine (15 cm^2)","deltaMin":4.1,"sd":8}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":145,"countries":["United States","Canada","France","Germany","Italy","Spain","Switzerland"]},"refs":{"pmids":["25755685","23982674"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":227,"n":1582},"commonTop":["Application site erythema","Application site pruritus","Nausea","Fall","Diarrhoea"]}}